<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03368690</url>
  </required_header>
  <id_info>
    <org_study_id>N201706026</org_study_id>
    <nct_id>NCT03368690</nct_id>
  </id_info>
  <brief_title>Effects of Polyphenolic Extract From Pine Bark on the Inattention and Hyperactivity in Patients With Attention Deficit Hyperactivity Disorder Based on the Antioxidative Status.</brief_title>
  <official_title>Effects of Polyphenolic Extract From Pine Bark on the Inattention and Hyperactivity in Patients With Attention Deficit Hyperactivity Disorder Based on the Antioxidative Status.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators will investigate the effects of polyphenolic extract from
      pine bark on the inattention and hyperactivity in patients with attention deficit
      hyperactivity disorder (ADHD) based on antioxidative status.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Swanson, Nolan and Pelham Teacher and Parent Rating Scale (Snap-IV)</measure>
    <time_frame>Change baseline four weeks of the experiment.</time_frame>
    <description>It is used to evaluate the inattention, impulsivity and hyperactivity for children and adolescent with ADHD as rated by parents and teachers. When Inattention/Hyperactivity-impulsivity subscales approach P85, the participants are going to the next steps.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adult ADHD Self-Report Scale-V1.1 (ASRS-V1.1) or Individual Subjective Perception Job Stress Scale (ISPJSS)</measure>
    <time_frame>Change baseline four weeks of the experiment.</time_frame>
    <description>It is used to evaluate the inattention, impulsivity and hyperactivity for adult with ADHD as rated by participants. The scores of ASRS-V1.1 more than 17, that can be going to the next steps.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conners' Continuous Performance Test (CPT-III)</measure>
    <time_frame>Change baseline four weeks of the experiment.</time_frame>
    <description>It is used to evaluate the inattention, impulsivity and vigilance for subjects with ADHD. T-score &gt; 60 approach clinical standard.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver function</measure>
    <time_frame>Change baseline four weeks of the experiment.</time_frame>
    <description>Serum AST,ALT and bilirubin-total are in units per liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney function</measure>
    <time_frame>Change baseline four weeks of the experiment.</time_frame>
    <description>Serum BUN,Creatine and urine acid are in milligram per deciliter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>Change baseline four weeks of the experiment.</time_frame>
    <description>Serum HDL-Cho, LDL-Cho, triglyceride and total cholesterol are in milligram per deciliter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology</measure>
    <time_frame>Change baseline four weeks of the experiment.</time_frame>
    <description>Serum WBC in 1000/uL , RBC in 1000000/uL, hemoglobin in gram per deciliter, hematocrit in percentage , MCV in femtoliter , MCH in picogram, MCHC in gram per deciliter, platelet in 1000/uL ; neutrophils, lymphocytes, monocytes, eosinophils and basophils are in percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron status</measure>
    <time_frame>Change baseline four weeks of the experiment.</time_frame>
    <description>Serum iron, ferritin and TIBC are in microgram per deciliter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antioxidative status</measure>
    <time_frame>Change baseline four weeks of the experiment.</time_frame>
    <description>Thiobarbituric acid-reactive substance and glutathione/oxidized glutathione ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary history</measure>
    <time_frame>Change baseline four weeks of the experiment.</time_frame>
    <description>To analyze nutrition status of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour recall method</measure>
    <time_frame>Change baseline four weeks of the experiment.</time_frame>
    <description>To analyze nutrition status of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food frequency questionnaire</measure>
    <time_frame>Change baseline four weeks of the experiment.</time_frame>
    <description>To analyze nutrition status of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Three-day dietary record.</measure>
    <time_frame>Change baseline four weeks of the experiment.</time_frame>
    <description>To analyze nutrition status of participants.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>Oligopin®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary supplement, Polyphenolic extract from pine bark. This group receives a nutritional supplement for a period of 10 weeks.
Children and adolescent 20-50 kg body weight: 25 mg Oligopin®/day; &gt; 50 kg body weight: 50 mg Oligopin®/day Adults 40-60 kg body weight: 100 mg Oligopin®/day; &gt; 60 kg body weight: 150 mg Oligopin®/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo treatment ( identical capsules containing maltodextrin and magnesium stearate )</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oligopin®</intervention_name>
    <description>At the treatment period (0th to 4th week of the experiment), subjects with ADHD will receive 1~3 capsules of polyphenolic extract from pine bark (25mg or 50 mg Oligopin per capsule) according to their body weight and age. The 5th to 6th week will be the washout period. The control group and Oligopin group will be cross-over at 7th week to 10th week of the experiment.</description>
    <arm_group_label>Oligopin®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>At the treatment period (0th to 4th week of the experiment), subjects with ADHD will receive 1~3 capsules of polyphenolic extract from pine bark (25mg or 50 mg Oligopin per capsule) according to their body weight and age. The 5th to 6th week will be the washout period. The control group and Oligopin group will be cross-over at 7th week to 10th week of the experiment.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Children or adolescent with attention deficit hyperactivity disorder (ADHD) whose age
             reach 7 but under 20 and were not treated with ADHD drugs, antihypertensive drugs and
             dietary supplements more than 4 weeks.

          2. Adults with attention deficit hyperactivity disorder (ADHD) aged from 20 to 65 and
             were not treated with antihypertensive drugs and dietary supplements more than 4
             weeks.

        Exclusion Criteria:

          1. Children or adolescent treated with ADHD drugs, antihypertensive drugs and dietary
             supplements

          2. Adults treated with antihypertensive drugs and dietary supplements

          3. Nervous system diseases (including brain or other central nervous system diseases,
             e.g. epilepsy)

          4. Autism spectrum disorder

          5. Intellectual disability

          6. Other mental disorders (e.g. Schizophrenia, Bipolar Disorder, Major depressive
             disorder, Anxiety Disorder, Personality disorders, Conduct disorder, Tourette
             Syndrome.)

          7. Hepatic, renal, gastrointestinal and cardiovascular disorders

          8. Biochemical abnormality
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Suh-Ching Yang</last_name>
    <phone>+886-2-2736-1661</phone>
    <phone_ext>6553</phone_ext>
    <email>sokei@tmu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taipei Medical University - Shuang Ho Hospital</name>
      <address>
        <city>New Taipei City</city>
        <zip>23561</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>I-Cheng Lin</last_name>
      <phone>886-2-22490088</phone>
      <phone_ext>79212</phone_ext>
      <email>12023@s.tmu.edu.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taiwan Adventist Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>10556</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Su</last_name>
      <phone>886-2-27718151</phone>
      <phone_ext>2692</phone_ext>
      <email>alexhsu588@yahoo.com.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2017</study_first_submitted>
  <study_first_submitted_qc>December 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2017</study_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polyphenolic extract from pine bark, Antioxidant, Attention deficit/hyperactivity disorder.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

